Advicenne Receives MHRA Approval to Market Sibnayal™

Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA
July 02, 2021 01:00 ET
| Source:
Advicenne
Advicenne
A
                                                                                                  
Paris, France, 2
nd July 2021 – 7 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that the Medicines & Healthcare products Regulatory Agency (MHRA) has today granted marketing authorisation for Sibnayal™ (ADV7103) in the UK, for the treatment of distal renal tubular acidosis (dRTA).
With this authorization, and following the recent approval by the European Commission to market Sibnayal™ for the treatment of dRTA in the European Union, Advicenne is now able to bring to market in the EU and the UK the first and only label-approved drug for the treatment of dRTA in adults, adolescents and children aged one year and older. Advicenne now has the opportunity to make a significant difference to patients suffering from dRTA, classified as an orphan condition in Europe.

Related Keywords

United Kingdom , United States , Paris , France General , France , Ashley Tapp , Mary Jane Elliott , Davide Salvi , Advicenne Euronext , David Solomon , Didier Laurens , European Union , European Commission , Regulatory Agency , Consilium Strategic Communications , Advicenne Receives , Market Sibnayal , Chief Executive Officer , United Kingdon , Euronext Paris , Euronext Brussels , Jane Elliott , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , பாரிஸ் , பிரான்ஸ் , ஆஷ்லே தட்டவும் , மேரி ஜேன் எலியட் , டேவிட் சால்வி , டேவிட் சாலமன் , டிடீயர் லாரன்ஸ் , ஐரோப்பிய தொழிற்சங்கம் , ஐரோப்பிய தரகு , கொன்சில்ிும் மூலோபாய தகவல்தொடர்புகள் , தலைமை நிர்வாகி அதிகாரி , ஒன்றுபட்டது கிஂக்டந் , ஜேன் எலியட் ,